




STUDY ENDPOINTS






- Technical success (endograft- and branch-related)
- 30-day MAE (kidney injury, MI, respiratory failure, paraplegia, stroke, bowel ischemia)
- Freedom from endograft & branch instability at 1-year
- CT-scan evaluation at 1, 6, and 12 months




ANATOMICAL DATA

	Extent I-III (n = 32)	Extent IV (n = 32)	Total (N = 64)	P value
Aortic pathology				
Acute or subacute dissection	4 (12.5)	0 (0.0)	4 (6.2)	.002
Chronic dissection	4 (12.5)	0 (0.0)	4 (6.2)	
Degenerative aneurysm	23 (71.9)	19 (59.4)	42 (65.6)	
Intramural hematoma	0 (0.0)	1 (3.1)	1 (1.6)	
Penetrating aortic ulcer	0 (0.0)	3 (9.4)	3 (4.7)	
Pseudoaneurysm	1 (3.1)	9 (28.1)	10 (15.6)	
Crawford classification				
Extent I	0 (0.0)	11 (34.3)	11 (17.2)	<.001
Extent II	0 (0.0)	15 (46.9)	15 (23.4)	
Extent III	0 (0.0)	6 (18.7)	6 (9.3)	
Extent IV	32 (100)	0 (0.0)	32 (50)	
Aortic status				
Contained rupture	2 (6.3)	6 (18.7)	8 (12.5)	.028
Non ruptured, symptomatic	20 (62.5)	11 (34.4)	31 (48.4)	
Non ruptured, asymptomatic	10 (31.2)	15 (46.9)	25 (39.1)	




DEMOGRAPHICS

	Extent I-III (n = 32)	Extent IV (n = 32)	Total (N = 64)	P value
Age, years	71.3 ± 8.9	77.6 ± 5.2	74.5 ± 7.5	.001
Male gender	22 (68.8)	26 (81.2)	48 (75.0)	
BMI, kg/m ²	27.3 ± 5.5	24.9 ± 6.4	26.0 ± 6.0	.184
Hypertension*	29 (90.6)	31 (96.9)	60 (93.8)	.302
Hypercholesterolemia	18 (56.2)	25 (78.1)	43 (67.2)	.062
Tobacco use	13 (40.6)	19 (59.4)	32 (50.0)	.354
COPD [†]	11 (34.4)	17 (53.1)	28 (43.8)	.351
Diabetes	4 (12.5)	5 (15.6)	9 (14.1)	.793
Chronic kidney disease*	6 (18.8)	10 (31.2)	16 (25.0)	.378
Dialysis	0 (0.0)	2 (6.2)	2 (3.1)	.351
Coronary artery disease*	10 (31.2)	10 (31.2)	20 (31.2)	1.000
Peripheral artery disease*	5 (15.6)	6 (18.8)	11 (17.2)	.740
Prior stroke or TIA	4 (12.5)	6 (18.8)	10 (15.6)	.491
Prior endovascular repair				.035
EVAR	2 (6.3)	6 (18.7)	8 (12.5)	
TEVAR	9 (28.1)	1 (3.1)	10 (15.6)	
EVAR + TEVAR	1 (3.1)	0 (0.0)	1 (1.6)	
Prior open aortic repair				.251
Ascending/aortic	6 (18.8)	3 (9.3)	9 (14.1)	
Thoracic	1 (3.1)	0 (0.0)	1 (1.6)	
Abdominal	3 (9.4)	4 (12.5)	7 (10.9)	
Thoracoabdominal	0 (0.0)	2 (6.2)	2 (3.1)	




PROCEDURAL DATA

	Extent I-III (n = 32)	Extent IV (n = 32)	Total (N = 64)	P value
Femoral access				
Percutaneous, bilateral	19 (59.4)	18 (56.2)	37 (57.8)	.035
Surgical, bilateral	11 (34.4)	5 (15.6)	16 (25.0)	
Percutaneous, unilateral	2 (6.2)	9 (28.1)	11 (17.2)	
Upper arm access				
No	8 (25.0)	4 (12.5)	12 (18.8)	.026
Left	14 (43.8)	24 (75.0)	38 (59.4)	
Right	10 (31.2)	4 (12.5)	14 (21.9)	
Proximal E-NSIDE diameter				
33 mm	6 (18.8)	14 (43.8)	20 (31.2)	.031
38 mm	26 (81.2)	18 (56.2)	44 (68.8)	
Distal E-NSIDE diameter				
26 mm	25 (78.1)	23 (71.9)	48 (75.0)	.564
30 mm	7 (21.9)	9 (28.1)	16 (25.0)	
Thoracic aorta coverage, cm	24.5 ± 6.7	16.4 ± 16.6	19.2 ± 14.2	.275
Prophylactic spinal drainage	12 (37.5)	5 (15.6)	17 (26.6)	.048
Adjunctive thoracic endograft	23 (71.9)	6 (18.8)	29 (45.3)	<.001
Adjunctive distal bifurcated endograft	13 (40.1)	20 (62.5)	33 (51.5)	.728

30-DAY OUTCOMES

	Extent I-III (n = 32)	Extent IV (n = 32)	Total (N = 64)	P value
Mortality	2 (6.3)	3 (9.3)	5 (7.8)	.697
Any MAE	7 (21.9)	11 (34.4)	18 (28.1)	.266
EBL >1000 ml	2 (6.2)	3 (9.4)	5 (7.8)	.641
Myocardial infarction	1 (3.1)	0 (0.0)	1 (1.6)	1.00
Respiratory failure	2 (6.2)	2 (6.2)	4 (6.2)	1.00
Acute kidney insufficiency	3 (9.4)	6 (18.8)	9 (14.1)	.281
GI complications	0 (0.0)	0 (0.0)	0 (0.0)	1.00
Stroke	0 (0.0)	1 (3.1)	1 (1.6)	.313
SCI				
No	30 (93.8)	29 (90.6)	59 (92.2)	
Minority deficit	1 (3.1)	2 (6.2)	3 (4.7)	
Motor not able to ambulate	1 (3.1)	1 (3.1)	2 (3.1)	
Early reintervention	5 (15.6)	5 (15.3)	10 (15.3)	.510
Access site complication	2 (6.2)	1 (3.1)	3 (4.7)	
Branch complication	2 (6.2)	2 (6.2)	4 (6.2)	
Main graft complication	1 (3.1)	0 (0.0)	1 (1.6)	









* Mortality: 25% in ruptured, 5% in non-ruptured

1-YEAR OUTCOMES

Median follow-up: 11 months

- 2 deaths after 30 days, not aortic related
- No endograft-related reinterventions
- 7 target vessel-related reinterventions:
 - 1 SMA occlusion
 - 3 symptomatic renal artery occlusion
 - 3 target vessel endoleak



CONCLUSIONS

- First study to evaluate an inner-branched off-the-shelf device for urgent TAAA repair, with high technical success rate (97%), acceptable mortality (9%) and SCI (8%) rates, and satisfactory early and 1-year results
- Main limitation: low number of ruptured aneurysms (13%)
- Advantages of the E-nside in urgent setting: 4 graft size configurations, preloaded branches
- Larger experience and longer follow-up needed

A 3D model of the E-nside stent-graft device, showing its inner-branched structure. The slide includes the VEITH SYSTEMS logo and the text 'CENTRO DE ESPECIALIDAD EN CIRUGIA VASCULAR'.

